CytomX Therapeutics Performance dei guadagni passati
Il passato criteri di controllo 3/6
CytomX Therapeutics has been growing earnings at an average annual rate of 21.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 10.3% per year.
Informazioni chiave
21.3%
Tasso di crescita degli utili
29.6%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 10.3% |
| Rendimento del capitale proprio | n/a |
| Margine netto | 9.3% |
| Prossimo aggiornamento sui guadagni | 07 Nov 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
Oct 26
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Ripartizione dei ricavi e delle spese
Come CytomX Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 120 | 11 | 31 | 83 |
| 31 Mar 24 | 119 | 17 | 30 | 79 |
| 31 Dec 23 | 101 | -1 | 30 | 78 |
| 30 Sep 23 | 95 | -10 | 30 | 73 |
| 30 Jun 23 | 79 | -42 | 34 | 87 |
| 31 Mar 23 | 68 | -71 | 38 | 97 |
| 31 Dec 22 | 53 | -99 | 40 | 107 |
| 30 Sep 22 | 21 | -149 | 42 | 129 |
| 30 Jun 22 | 27 | -143 | 43 | 127 |
| 31 Mar 22 | 30 | -132 | 40 | 122 |
| 31 Dec 21 | 37 | -116 | 39 | 114 |
| 30 Sep 21 | 66 | -72 | 39 | 100 |
| 30 Jun 21 | 66 | -64 | 36 | 95 |
| 31 Mar 21 | 67 | -61 | 36 | 92 |
| 31 Dec 20 | 68 | -65 | 36 | 113 |
| 30 Sep 20 | 92 | -54 | 36 | 127 |
| 30 Jun 20 | 85 | -63 | 36 | 131 |
| 31 Mar 20 | 78 | -76 | 37 | 138 |
| 31 Dec 19 | 27 | -133 | 37 | 132 |
| 30 Sep 19 | 61 | -99 | 37 | 123 |
| 30 Jun 19 | 62 | -99 | 36 | 123 |
| 31 Mar 19 | 75 | -83 | 36 | 118 |
| 31 Dec 18 | 60 | -85 | 34 | 104 |
| 30 Sep 18 | 75 | -52 | 32 | 96 |
| 30 Jun 18 | 87 | -39 | 30 | 98 |
| 31 Mar 18 | 74 | -50 | 27 | 100 |
| 31 Dec 17 | 72 | -43 | 26 | 92 |
| 30 Sep 17 | 51 | -58 | 23 | 87 |
| 30 Jun 17 | 30 | -62 | 22 | 71 |
| 31 Mar 17 | 24 | -51 | 21 | 56 |
| 31 Dec 16 | 15 | -59 | 20 | 55 |
| 30 Sep 16 | 11 | -57 | 19 | 49 |
| 30 Jun 16 | 9 | -57 | 18 | 45 |
| 31 Mar 16 | 8 | -50 | 16 | 37 |
| 31 Dec 15 | 8 | -42 | 13 | 28 |
| 30 Sep 15 | 8 | -36 | 11 | 23 |
| 30 Jun 15 | 8 | -26 | 8 | 18 |
| 31 Mar 15 | 6 | -24 | 7 | 17 |
| 31 Dec 14 | 5 | -35 | 7 | 28 |
| 31 Dec 13 | 1 | -19 | 5 | 11 |
Guadagni di qualità: CTMX has high quality earnings.
Margine di profitto in crescita: CTMX became profitable in the past.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: CTMX has become profitable over the past 5 years, growing earnings by 21.3% per year.
Accelerare la crescita: CTMX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Guadagni vs Settore: CTMX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: CTMX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.